Tyrosine kinase-IN-6

Cat. No.: HY-155812: Data Sheet Handling Instructions
FAQs
Technical Support

Tyrosine kinase-IN-6 is a potent and promising RON splice variants inhibitor with anti-cancer and o?antineoplastic effects.

For research use only. We do not sell to patients.

Tyrosine kinase-IN-6 Chemical Structure

CAS No. : 2377507-01-0

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

Tyrosine kinase-IN-6 is a potent and promising RON splice variants inhibitor with anti-cancer and o?antineoplastic effects^[1].

Cellular Effect

Cell Line	Type	Value	Description	References
ASPC1	GI₅₀	0.46 μM Compound: 15f	Antiproliferative activity against human ASPC1 cells harbouring KRAS G12D mutant and RON delta 165 assessed as cell growth inhibition measured after 72 hrs by MTS assay Antiproliferative activity against human ASPC1 cells harbouring KRAS G12D mutant and RON delta 165 assessed as cell growth inhibition measured after 72 hrs by MTS assay	[PMID: 37736180]
CAPAN-1	GI₅₀	0.55 μM Compound: 15f	Antiproliferative activity against human CAPAN-1 cells harbouring KRAS G12V mutant and RON delta 155 assessed as cell growth inhibition measured after 72 hrs by MTS assay Antiproliferative activity against human CAPAN-1 cells harbouring KRAS G12V mutant and RON delta 155 assessed as cell growth inhibition measured after 72 hrs by MTS assay	[PMID: 37736180]
HCT-15	GI₅₀	0.29 μM Compound: 15f	Antiproliferative activity against human HCT-15 cells harbouring KRAS G13D mutant and RON delta 160 assessed as cell growth inhibition measured after 72 hrs by MTS assay Antiproliferative activity against human HCT-15 cells harbouring KRAS G13D mutant and RON delta 160 assessed as cell growth inhibition measured after 72 hrs by MTS assay	[PMID: 37736180]
HT-29	GI₅₀	0.609 μM Compound: 15f	Antiproliferative activity against human HT-29 cells harbouring wild-type KRAS and RON delta 160 assessed as cell growth inhibition measured after 72 hrs by MTS assay Antiproliferative activity against human HT-29 cells harbouring wild-type KRAS and RON delta 160 assessed as cell growth inhibition measured after 72 hrs by MTS assay	[PMID: 37736180]
KM12C	GI₅₀	0.007 μM Compound: 15f	Antiproliferative activity against human KM12-C cells harbouring wild-type KRAS and RON delta 160 assessed as cell growth inhibition measured after 72 hrs by MTS assay Antiproliferative activity against human KM12-C cells harbouring wild-type KRAS and RON delta 160 assessed as cell growth inhibition measured after 72 hrs by MTS assay	[PMID: 37736180]
LS-411N	GI₅₀	1.01 μM Compound: 15f	Antiproliferative activity against human LS-411N cells harbouring wild-type KRAS and RON delta 155 assessed as cell growth inhibition measured after 72 hrs by MTS assay Antiproliferative activity against human LS-411N cells harbouring wild-type KRAS and RON delta 155 assessed as cell growth inhibition measured after 72 hrs by MTS assay	[PMID: 37736180]
MIA PaCa-2	GI₅₀	0.63 μM Compound: 15f	Antiproliferative activity against human MIA PaCa-2 cells harbouring KRAS G12C mutant and RON delta 160 assessed as cell growth inhibition measured after 72 hrs by MTS assay Antiproliferative activity against human MIA PaCa-2 cells harbouring KRAS G12C mutant and RON delta 160 assessed as cell growth inhibition measured after 72 hrs by MTS assay	[PMID: 37736180]
PANC-03-27	GI₅₀	7.34 μM Compound: 15f	Antiproliferative activity against human Panc 03.27 cells harbouring KRAS G12V mutant and RON delta 155 assessed as cell growth inhibition measured after 72 hrs by MTS assay Antiproliferative activity against human Panc 03.27 cells harbouring KRAS G12V mutant and RON delta 155 assessed as cell growth inhibition measured after 72 hrs by MTS assay	[PMID: 37736180]
PANC-1	GI₅₀	2.4 μM Compound: 15f	Antiproliferative activity against human PANC-1 cells harbouring KRAS G12D mutant and RON delta 155 assessed as cell growth inhibition measured after 72 hrs by MTS assay Antiproliferative activity against human PANC-1 cells harbouring KRAS G12D mutant and RON delta 155 assessed as cell growth inhibition measured after 72 hrs by MTS assay	[PMID: 37736180]
SW-620	GI₅₀	0.32 μM Compound: 15f	Antiproliferative activity against human SW620 cells harbouring KRAS G12 V mutant and RON delta 155 assessed as cell growth inhibition measured after 72 hrs by MTS assay Antiproliferative activity against human SW620 cells harbouring KRAS G12 V mutant and RON delta 155 assessed as cell growth inhibition measured after 72 hrs by MTS assay	[PMID: 37736180]
SW1417	GI₅₀	0.32 μM Compound: 15f	Antiproliferative activity against human SW1417 cells harbouring wild-type KRAS and RON delta 155 assessed as cell growth inhibition measured after 72 hrs by MTS assay Antiproliferative activity against human SW1417 cells harbouring wild-type KRAS and RON delta 155 assessed as cell growth inhibition measured after 72 hrs by MTS assay	[PMID: 37736180]
SW480	GI₅₀	0.34 μM Compound: 15f	Antiproliferative activity against human SW480 cells harbouring KRAS G12V mutant and RON delta 155 assessed as cell growth inhibition measured after 72 hrs by MTS assay Antiproliferative activity against human SW480 cells harbouring KRAS G12V mutant and RON delta 155 assessed as cell growth inhibition measured after 72 hrs by MTS assay	[PMID: 37736180]

Molecular Weight

695.73

Formula

C₃₇H₃₁F₂N₅O₅S

CAS No.

2377507-01-0

SMILES

O=C(C1=C(OCC)C=CN(C2=CC=C(F)C=C2)C1=O)NC3=CC=C(OC4=C5C(C=C(C6=NC=C(CN7CCOCC7)C=C6)S5)=NC=C4)C(F)=C3

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Hyun Ryu, Hyojin Kim, et al. Discovery of Novel, Thienopyridine-Based Tyrosine Kinase Inhibitors Targeting Tumorigenic RON Splice Variants. ACS Med. Chem. Lett. 2023, 14, 9, 1198–1207